Phase I/II Study Of Herceptin Combined With OSI-774 In The First-Line Treatment Of Metastatic Breast Cancer Associated With HER2/Neu Overexpression
Phase of Trial: Phase I/II
Latest Information Update: 15 Apr 2016
At a glance
- Drugs Erlotinib (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- 08 Apr 2016 Recommended Dose for Phase II added as primary endpoint hence trial focus changed from TU to TU + AR.
- 17 Jun 2011 Trial phase changed from II to I/II as reported by ClinicalTrials.gov.
- 17 Jun 2011 Planned end date changed from 1 Oct 2010 to 1 Oct 2012 as reported by ClinicalTrials.gov.